Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from John Vandermosten

ACHV: Topline Data from ORCA-2 Smoking Cessation Trial

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

ALQGC: New Capital and New Investors Added

By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT

GBS: Institutional Review Board Approval for Glucose

By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

TENX: 2021 Financial and Operational Review

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

BLRX: 2021 Results

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

RVPH: 2021 Results

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT

TLSA: KOL Discussion and SPMS 6-Month Results

By John Vandermosten, CFA NASDAQ:TLSA Introduction

inkl

Read news from The Economist, FT, and more,
with one subscription

ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

LPCN: 2021 Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

DRIO: Future Brightens with $40M Raise & Sanofi Deal

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT

NOVN: A Banner Year for Novan - 2021 Results

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT

PLX: MAA Submitted

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT

DYAI: Don't Put All Your Eggs in One Basket

By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT

SQZ: IND Cleared for Enhanced APCs

By John Vandermosten, CFA NYSE:SQZ READ THE FULL SQZ RESEARCH REPORT

Get all your
news in one place.

100’s of premium titles.
One news app.

ACHV: The Final Phase III Begins

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

BIOAF: Third Quarter Results

By John Vandermosten, CFA OTC:BIOAF READ THE FULL BIOAF RESEARCH REPORT

BLRX: Initiating on BioLineRx: Mobilizing the Troops with Motixafortide

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

DRIO: 2022 Outlook, Physimax Acquisition

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT

Get all your
news in one place.

100’s of premium titles.
One news app.

MDXG: Model Updates

By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT

LTRN: Multiple Collaborations Illuminating Way Forward

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT

HTBX: RapidVax Unveiled; Elusys Acquisition

By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT

People

John Vandermosten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Silicon Valley Bank

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

260,361 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play